Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase

Experimental Hematology

Volumn 40, Issue 8, 2012, Pages 657-665

  Hermanova, Ivana ^a   Zaliova, Marketa ^a   Trka, Jan ^a   Starkova, Julia ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFANT; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; BLAST CRISIS; CELL LINE, TUMOR; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, MESSENGER;

EID: 84863991018     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.04.005     Document Type: Article

References (35)

1. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-615.
2. Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999, 13:335-342.
3. Sallan S.E., Hitchcock-Bryan S., Gelber R., Cassady J.R., Frei E., Nathan D.G. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983, 43:5601-5607.
4. Tallal L., Tan C., Oettgen H., et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970, 25:306-320.
5. Jaffe N., Traggis D., Das L., et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971, 31:942-949.
6. Sutow W.W., Garcia F., Starling K.A., Williams T.E., Lane D.M., Gehan E.A. L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group. Cancer 1971, 28:819-824.
7. Capizzi R.L., Bertino J.R., Skeel R.T., et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971, 74:893-901.
8. Cooney D.A., Capizzi R.L., Handschumacher R.E. Evaluation of L-asparagine metabolism in animals and man. Cancer Res 1970, 30:929-935.
9. Asselin B.L., Ryan D., Frantz C.N., et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989, 49:4363-4368.
10. Holleman A., den Boer M.L., Kazemier K.M., Janka-Schaub G.E., Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003, 102:4541-4546.
11. Haskell C.M., Canellos G.P. l-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 1969, 18:2578-2580.
12. Leslie M., Case M.C., Hall A.G., Coulthard S.A. Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br J Haematol 2006, 132:740-742.
13. Aslanian A.M., Fletcher B.S., Kilberg M.S. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 2001, 357:321-328.
14. Hutson R.G., Kitoh T., Moraga Amador D.A., Cosic S., Schuster S.M., Kilberg M.S. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol 1997, 272:C1691-C1699.
15. Holleman A., Cheok M.H., den Boer M.L., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
16. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000, 96:1094-1099.
17. Krejci O., Starkova J., Otova B., et al. Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia 2004, 18:434-441.
18. Stams W.A., den Boer M.L., Beverloo H.B., et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003, 101:2743-2747.
19. Stams W.A., den Boer M.L., Holleman A., et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005, 105:4223-4225.
20. Fine B.M., Kaspers G.J., Ho M., Loonen A.H., Boxer L.M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005, 65:291-299.
21. Appel I.M., den Boer M.L., Meijerink J.P., Veerman A.J., Reniers N.C., Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006, 107:4244-4249.
22. Su N., Pan Y.X., Zhou M., Harvey R.C., Hunger S.P., Kilberg M.S. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2008, 50:274-279.
23. Kim D.H., Moldwin R.L., Vignon C., et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood 1996, 88:785-794.
24. Bird M.C., Bosanquet A.G., Forskitt S., Gilby E.D. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res 1986, 10:445-449.
25. Pieters R., Huismans D.R., Leyva A., Veerman A.J. Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 1989, 59:217-220.
26. Pieters R., Loonen A.H., Huismans D.R., et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990, 76:2327-2336.
27. Kaspers G.J., Veerman A.J., Pieters R., et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997, 90:2723-2729.
28. Drexler H.G., Macleod R.A. History of leukemia-lymphoma cell lines. Hum Cell 2010, 23:75-82.
29. Leupin N., Kuhn A., Hugli B., et al. Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. Br J Haematol 2006, 135:520-523.
30. Barbosa-Tessmann I.P., Chen C., Zhong C., et al. Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements. J Biol Chem 2000, 275:26976-26985.
31. Bunpo P., Cundiff J.K., Reinert R.B., Wek R.C., Aldrich C.J., Anthony T.G. The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase. J Nutr 2010, 140:2020-2027.
32. Bunpo P., Dudley A., Cundiff J.K., et al. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem 2009, 284:32742-32749.
33. Patel N., Krishnan S., Offman M.N., et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 2009, 119:1964-1973.
34. Rousseau J., Gagne V., Labuda M., et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011, 118:5883-5890.
35. Iwamoto S., Mihara K., Downing J.R., Pui C.H., Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117:1049-1057.